Scribe Therapeutics, Inc. is focused on developing STX-1150, a therapeutic designed to silence PCSK9 gene expression utilizing proprietary ELXR technology. The company has conducted extensive preclinical studies demonstrating STX-1150's efficacy, safety, and durability in reducing PCSK9 levels and impacting LDL-C levels across various models including human hepatocytes, transgenic mice, and non-human primates (NHPs).
Not disclosed in the provided filing text.
Not disclosed in the provided filing text.
This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.
The expected date is Jul 27, 2026. Shares are priced at $15.00. Underwriters on the deal include Leerink Partners LLC, Guggenheim Securities, LLC, Wells Fargo Securities, LLC. Scribe Therapeutics, Inc. is headquartered in United States and incorporated in DE. It is classified under Biological Products, (No Diagnostic Substances).
Scribe Therapeutics, Inc. has filed 3 times, starting with a S1/A on Jul 10, 2026.
The dates below are calculated from widely-used industry conventions, not from this offering's own disclosed terms — DiscoverIPO does not have a structured source for the actual figures. Treat them as reference points, not confirmed dates.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Scribe Therapeutics, Inc..
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/scribe-therapeutics" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Scribe Therapeutics, Inc. — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/scribe-therapeutics?theme=light as the src instead.
https://www.discoveripo.com/ipo/scribe-therapeutics/opengraph-image
Scribe Therapeutics, Inc. IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/scribe-therapeutics?utm_source=embed&utm_medium=text&utm_campaign=scribe-therapeutics
Get emailed when Scribe Therapeutics, Inc.'s terms, price, or expected date change — no weekly noise, just this company.
Scribe Therapeutics, Inc. is expected to list on Jul 27, 2026.
Registration statement filed with the U.S. Securities and Exchange Commission. Retrieved Aug 27, 2026.
View the original filing on SEC EDGAR →How this offering's SEC filings changed over time. Only SEC-sourced filings are compared here — exchange calendars publish only their latest figures, with no history to diff against.
Initial filing.
No tracked deal terms changed in this amendment.
Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy